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Purpose: To examine the association of polymorphisms in ATM (codon 158), GSTP1 (codon 105), SOD2 (codon 16),
TGFB1 (position −509), XPD (codon 751), and XRCC1 (codon 399) with the risk of severe erythema after breast
conserving radiotherapy.
Methods and materials: Retrospective analysis of 83 breast cancer patients treated with breast conserving radiotherapy.
A total dose of 50.4 Gy was administered, applying 1.8 Gy/fraction within 42 days. Erythema was evaluated according to
the Radiation Therapy Oncology Group (RTOG) score. DNA was extracted from blood samples and polymorphisms were
determined using either the Polymerase Chain Reaction based Restriction-Fragment-Length-Polymorphism (PCR-RFL)
technique or Matrix-Assisted-Laser-Desorption/Ionization –Time-Of-Flight-Mass-Spectrometry (MALDI-TOF). Relative excess
heterozygosity (REH) was investigated to check compatibility of genotype frequencies with Hardy-Weinberg equilibrium
(HWE). In addition, p-values from the standard exact HWE lack of fit test were calculated using 100,000 permutations. HWE
analyses were performed using R.
Results: Fifty-six percent (46/83) of all patients developed erythema of grade 2 or 3, with this risk being higher for patients
with large breast volume (odds ratio, OR=2.55, 95% confidence interval, CI: 1.03–6.31, p= 0.041). No significant association
between SNPs and risk of erythema was found when all patients were considered. However, in patients with small breast
volume the TGFB1 SNP was associated with erythema (p=0.028), whereas the SNP in XPD showed an association in
patients with large breast volume (p= 0.046). A risk score based on all risk alleles was neither significant in all patients nor
in patients with small or large breast volume. Risk alleles of most SNPs were different compared to a previously identified
risk profile for fibrosis.
Conclusions: The genetic risk profile for erythema appears to be different for patients with small and larger breast
volume. This risk profile seems to be specific for erythema as compared to a risk profile for fibrosis.
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The treatment of malignant tumours by radiotherapy (RT)
is limited by the need to avoid unacceptable normal tissue
toxicity. Despite advances in RT-technique, treatment
modalities as well as therapeutic strategies, normal tissue
damage is still a limiting factor in radiotherapy. In this con-
text, late complications are especially important because
they are generally progressive and appear to be associated
with a lifelong risk [1]. In contrast, acute normal tissue tox-
icity is generally a transient phenomenon, with symptoms
settling within months after treatment. However, these
effects are not less clinically relevant, especially when accel-
erated fractionation schedules or adjuvant radiochemother-
apy treatment are used [2-4] with new substances often
increasing normal tissue toxicity, e.g. Cetuximab.
Both acute and late normal tissue effects are known to
vary considerably, ranging from negligible to severe, even
between patients treated with identical schedules. It has
been suggested that these variations in clinical radiosensi-
tivity mainly result from differences in genetically deter-
mined radiosensitivity, as only 30% of this variation can be
attributed to changes in treatment related parameters
[5,6]. In addition to clinical and genetic parameters for
radiation response, a number of patient-related confound-
ing factors exist influencing adverse effects definitely, some
of which probably have yet to be identified. Based on this
background, pronounced scientific interest is currently
being directed towards the use of genetic markers such as
single nucleotide polymorphisms (SNPs) as parameters for
the individual risk of experiencing radiation-induced nor-
mal tissue toxicity. Studies on the impact of SNPs are
either performed following the candidate gene approach
or employing genome-wide association (GWA) analysis.
So far, numerous studies have been performed, but the
results obtained are heterogeneous and often conflicting;
for reviews, see [7,8]. Even for the C-509 T polymorph-
ism in the transforming growth factor 1 (TGFB1) gene,
which represents one of the most studied SNPs, there
are several reports [9-13] showing that this polymorph-
ism promotes chronic inflammatory and fibrotic reac-
tions, but there are also data suggesting a lack of
association or even the opposite effect [14-17].
In addition to the identification of those SNPs which
are relevant for normal tissue toxicity, their functional
consequences concerning the involved molecular path-
ways and their mechanisms of action are currently of
great scientific interest. A respective consortium addres-
sing this topic has recently been established [18].
The discrepancies in the currently available data may be
attributed to the fact that with a frequency of about one
SNP every 160 to 180 bp [19-21], the vast majority of SNPs
are assumed to have no or a small effect on the respective
protein or functional pathway. respectively. Therefore indi-
vidual genetic characteristics must be determined by thecombination of several SNPs each one associated with a
small effect. This was indicated by previous studies [7,22]
which demonstrated a significant association with normal
tissue toxicity only if several - each of one only weakly
associated SNPs - were combined to a risk score. Such risk
scores can easily be created by adding the number of risk
alleles per patients and correlating the resulting numerical
value with the severity of the normal tissue toxicity.
It is discussed that a risk profile, based on a combin-
ation of SNPs in genes which are involved in relevant
pathways may vary for the type of normal tissue toxicity
scored [7], i.e. different endpoints are characterized by
different mosaic-like displays of certain SNPs.
This concept implies that it might be more informative to
analyse a certain combination of SNPs in independent stud-
ies rather than to change this combination within different
studies.
To date, such analyses have only been performed by
Andreassen et al. [10,14,23] using certain combinations of
SNPs all including SNPs in TGFB1, SOD2, XRCC1, XRCC3,
APEX and ATM genes and studying their association with
skin fibrosis in post-mastectomy radiotherapy patients.
While the agreement between the first two studies analysing
two different cohorts was fairly good [10,14], the third study
on a larger cohort of patients [14] failed to confirm the as-
sociation with radiation induced, indicating that future
studies should consider other combination of SNPs [7].
In our studies, we concentrated on six SNPs located in
genes (ATM, GSTP1, SOD2, TGFB1, XPD, XRCC1)
involved either in the induction or repair of DNA double-
strand breaks and therefore considered to be of relevance
for individual radiosensitivity. In a first report, the associ-
ation of these SNPs with the risk of late tissue effects was
analysed for breast cancer patients treated with breast con-
serving radiotherapy [22]. No significant association with
risk was obtained for any individual SNP, as indicated by
p-values ranging from 0.064 to 0.643. However, when these
SNPs were combined into a risk score, a highly significant
association (p=0.0005) was found.
We now investigated in a retrospective study on 83
breast cancer patients the association of these SNPs with
the risk of acute tissue toxicity in terms of erythema,
with special focus on the relevance of breast size. Ery-
thema grade 2 and more was used as clinical endpoint
determined by using the RTOG score. DNA extracted
from blood was used to determine the SNP status using
either PCR-RFLP or MALDI-TOF. The results imply that
fundamental differences exist concerning the risk profile
for late and acute tissue toxicity, respectively.
Material and methods
Patients
Blood samples were collected from 83 patients with
breast cancer (BC) Stage I/II (postmenopausal; mean age
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11.5, range 36–80) who had undergone breast conserving
surgery and adjuvant radiotherapy to the breast. This
cohort is independent of the one used in the previous
study adressing fibrosis [22]. Patients were recruited
from the Clinic for Radiotherapy and Radiation Oncology,
University Medical Center Hamburg-Eppendorf, and from
the Clinic of Radiotherapy, Radiation Oncology and
Nuclear Medicine, Vivantes Klinikum Neukölln, Berlin,
Germany. Ethical permission as well as informed consent
was obtained in advance. Experimental studies were
blinded for patient’s identity and clinical performance.
Seventy-seven patients were treated with 1.8 Gy per frac-
tion five times per week and six patients received 25 frac-
tions of 2.0 Gy, amounting to a total dose of 50.4 or 50 Gy,
respectively. 67% of patients received a boost of 9 or 10 Gy
administered in five fractions of 1.8 or 2 Gy, respectively.
75 patients received hormonotherapy with tamoxifen. At
50 Gy, prior to boost application, erythema of the breast,
excluding folds and scars, was evaluated using the RTOG
score. Scoring of acute toxicity was undertaken by a single
investigator. Four scores were defined: grade 0: no change
compared to baseline, grade 1: faint or dull erythema/ epil-
ation/ dry desquamation/ decreased sweating, grade 2: ten-
der or bright erythema, patchy moist desquamation or
moderate edema, grade 3: confluent moist desquamation,
pitting edema, grade 4: ulceration, hemorrhage, and necro-
sis. The study was approved by the local ethics committee.
Genotyping
DNA was extracted from the whole blood of the patients
using a genomic extraction kit (Macherey & Nagel,
Germany). DNA concentrations were determined using
a BioPhotometer (Eppendorf, Germany).
GSTP1 (codon 105, rs1695), TGFB1 (position −509,
rs1800469), and XRCC1 (codon 399, rs25487) genotypes
were determined using PCR-RFLP. The PCR reaction
was carried out using 100 ng of genomic DNA in a total
reaction volume of 25 μl using PuReTaq Ready-To-Go
PCR beads (Amersham, United Kingdom). Primer pairs
(Table 1) were used at a concentration of 10 pmol. For
GSTP1, cycling conditions were 95°C for 5 min, followed
by 35 cycles of 95°C for 30 sec, 60°C for 30 sec and 72°C
for 30 sec, with a final extension of 72°C for 5 min. The
PCR-product of 176 bp was digested with BsmAI at 55°C
for 3 h, forming fragments of 91 bp and 85 bp, which
were then resolved on 2% agarose gels. For TGFB1 and
XRCC1, cycling conditions were 2 min at 95°C, followed
by 35 cycles of 95°C for 45 sec, 60°C for 45 sec and 72°C
for 45 sec, or 5 min at 94°C followed by 34 cycles of 94°
C for 30 sec, 68°C for 60 sec and 72°C for 60 sec, with a
final extension of 72°C for 5 min, yielding PCR-products
of 419 bp or 615 bp, respectively. These products were
then digested using Bsu36I or MspI to form fragments of190 bp and 229 bp for TGFB1, or 376 bp and 239 bp for
XRCC1.
Genotyping for the polymorphisms in ATM (codon
1853, rs1501516), SOD2 (codon 16, rs4880) and XPD
(codon 751, rs13181) was performed by Bioglobe (Ham-
burg, Germany) employing the MassARRAYW system
(Sequenom, USA), applying the MassEXTENDW [24]
(hME) method and MALDI-TOF mass spectrometry for
analyte detection. Reactions were performed according
to the standard hME protocol recommended by the sys-
tem supplier. The protocol generates allele-specific ana-
lytes in a primer extension reaction applying the primer
directly adjacent to the SNP site. After sample condition-
ing, a MassARRAYW Analyzer Compact was used for
data acquisition, followed by automated data analysis
with TYPERW RT software version 3.4. Where necessary,
the results were reviewed and the operator was revised.
Assay design was successfully performed with platform-
specific software for the SNP sequence. Failed reactions/
samples were repeated. SNP assays were designed auto-
matically using the MassARRAY platform specific Assay
Design software. Additional information was obtained
from databases to aid in selecting highly specific primers.
For ATM, a second SNP (rs1801673) has been documen-
ted in the direct vicinity (next base pair) of the SNP of
interest (rs1801516). Therefore, the assay design was
modified to allow for the detection of potentially occurring
haplotypes, thus ensuring accurate results. Any risk of po-
tential overlap with the secondary SNP was prevented.
In all cases positive controls were included and am-
biguous results verified by means of replication.
Statistical analysis
Relative excess heterozygosity (REH) [25] was deter-
mined to check compatibility of genotype frequencies
with Hardy-Weinberg equilibrium (HWE). In addition,
p-values from the standard exact HWE lack of fit test
were calculated using 100,000 permutations. HWE ana-
lyses were performed using R.
Patients were divided into two groups with either no or
only moderate erythema (grade 0 and 1) or with severe
erythema (grade 2 and 3). Analyses were performed using
all patients and subgroups stratified by breast volume.
Small breast volume was defined as a volume< 750 cm3,
which is the median volume of all patients. Association
between breast volume and risk of erythema was tested
using the two-sided asymptotic Cochran-Armitage trend
test with odds ratio (OR) and asymptotic 95% confidence
intervals (CI) estimated using logistic regression.
Associations between erythema grade and each indi-
vidual SNP were tested using the two-sided exact
Cochran-Armitage trend test. ORs per increase in one
allele and exact 95% CIs were estimated using logistic
regression. No adjustment was performed for multiple
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Figure 1 Incidence of breast erythema in 83 patients treated by
breast conserving radiotherapy. Data are stratified for a breast
volume of 750 cm³. Grade of erythema was determined using the
RTOG score.
Table 1 SNP characteristics and population











ATM rs1801516 G/A 1853 Asp>Asn DNA repair — — 0.802 (0.350 – 1.861) 0.842




1.104 (0.670 – 1.815) 0.924
SOD2 rs4880 C/T 16 Ala> Val ROS pathway — — 1.798 (1.130 – 2.849) 0.037






0.993 (0.640 – 1.549) 0.987
XPD rs13181 A/C 751 Lys>Gln DNA repair — — 1.030 (0.640 – 1.656) 0.987




0.735 (0.460 – 1.164) 0.424
a major allele / minor allele.
b p-value of the exact Hardy-Weinberg equilibrium lack of fit test.
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number of risk alleles at five loci. Association with grade
of erythema was checked using the two-sided exact
Cochran-Armitage trend test assuming an additive effect
of both alleles. OR and exact 95%CI were estimated for
an increase in one risk allele. Unless stated otherwise, all
tests were performed using StatXact with a nominal type
I error level of 5%.
Results
Acute tissue toxicity
Figure 1 shows the distribution of skin erythema as
determined for 83 breast cancer patients using the
RTOG score. One patient exhibited no erythema, 36
patients experienced erythema grade 1, 39 grade 2, and
7 patients developed erythema grade 3, while none of
the patients showed grade 4. As reported previously
[26], a significant association was observed between the
risk of erythema and breast volume (OR= 2.55, 95% CI:
1.03–6.31, p = 0.041). This is illustrated in Figure 1
showing that 48 patients with a small breast volume had
a 46% risk to develop erythema of G2 or 3, in contrast
to a 69% risk for 35 patients with large breast volume.
No significant difference was observed in mean age or
other individual factors such as smoking habits (data not
shown). An analysis using the log-rank test also failed to
reveal differences with respect to adjuvant chemo- or
hormonal therapy, beam quality or fractionation regime.
Genotype analysis
DNA extracted from blood samples was used to determine
the genotype frequency of the six different polymorphisms
(Table 1). In the case of XPD-SNP, genotyping failed in one
sample, reducing the total number to 82 patients. The
obtained genotype frequencies were comparable to those
documented for control populations of European descend-
ent (www.ncbi.nlm.nih.gov). For SOD2, a relative excess
heterozygosity of 1.80 (1.13–2.85) was observed, indicatinga deviation from HWE (Table 1). This might result from
copy number variations, as documented for this locus [27]
(see also http://projects.tcag.ca/variation/). To avoid misin-
terpretation of the data, this SNP was excluded from further
analysis.
Table 2 shows the data obtained from the individual SNP
association analysis performed for all patients as well as
subgroups of patients with small and large breast volumes.
Analysing all patients yielded no statistically significant
association between erythema and any polymorphism, with
p-values ranging between 0.098 and 1 (Table 2, left part). In
contrast, a separate analysis of patients with small breast
volume revealed a significant allele-dose dependent associ-
ation for TGFB1 C-509 T (OR=3.10, 95% CI: 1.11–10.21,
p=0.028). No significant association was found for any of
Table 2 Association of SNPs with erythema for all patients as well as for the subgroups of patients with breast volume< or >750 cm³
all patients patients with breast volume <750 cm³ patients with breast volume ≥750 cm³
(n = 83) (n = 48) (n = 35)
Gene
(codon)
Genotype aa n (%) G0/1a G2/3a ORb 95% CIc Pd aa n (%) G0/1a G2/3a ORb 95% CIc Pd aa n (%) G0/1a G2/3a ORb 95% CIc Pd
ATM GG 63 (76) 28 35 1 36 (75) 20 16 1 27 (77) 8 19 1 0.19 – 5.68
(1853) GA 18 (22) 9 9 1.18 0.45 – 3.25 0.826 11 (23) 6 5 1.43 0.38 – 5.67 0.573 7 (20) 3 4 0.92 0.04 – 32.21 1.000
AA 2 (2) 0 2 1.38 0.20 – 10.59 1 (2) 0 1 2.05 0.15 – 32.15 1 (3) 0 1 0.84
GSTP1 AA 37 (45) 19 18 1 21 (44) 12 9 1 16 (46) 7 9 1
(105) AG 38 (45) 12 26 1.01 0.49 – 2.09 1.000 21 (44) 10 11 0.98 0.39 – 2.44 1.000 17 (48) 2 15 1.25 0.32 – 5.29 0.772
GG 8 (10) 6 2 1.02 0.24 – 4.35 6 (12) 4 2 0.96 0.15 – 5.97 2 (6) 2 0 1.56 0.10 – 28.03
TGFB1 CC 29 (35) 14 15 1 18 (38) 13 5 1 11 (31) 1 10 1
(pos-509) CT 40 (48) 18 22 1.26 0.65 – 2.50 0.530 24 (50) 12 12 3.10 1.11 –10.21 0.028 16 (46) 6 10 0.36 0.10 – 1.14 0.083
TT 14 (17) 5 9 1.59 0.42 – 6.24 6 (12) 1 5 9.58 1.23 – 104.30 8 (23) 4 4 0.13 0.01 – 1.29
XPD e GG 34 (42) 19 15 1 20 (43) 12 8 1 14 (40) 7 7 1
(751) GT 38 (46) 14 24 1.85 0.90 – 4.00 0.098 20 (43) 10 10 1.42 0.59 – 3.59 0.420 18 (51) 4 14 3.95 0.91 – 22.75 0.046
TT 10 (12) 3 7 3.44 0.81 – 16.01 7 (14) 3 4 2.03 0.34 – 12.89 3 (9) 0 3 15.62 0.84 – 517.40
XRCC1 GG 36 (43) 17 19 1 25 (52) 14 11 1 11 (31) 3 8 1
(399) GA 33 (40) 13 20 1.02 0.54 – 1.93 1.000 17 (35) 9 8 1.13 0.46 – 2.76 0.840 16 (46) 4 12 0.62 0.20 – 1.84 0.464
AA 14 (17) 7 7 1.04 0.29 – 3.73 6 (12) 3 3 1.27 0.21 – 7.63 8 (23) 4 4 0.39 0.04 – 3.39
a Patients with erythema of grade 0 or 1 and grade 2 or 3.
b Odds ratio per allele.
c 95% confidence interval.
d Two-sided p-value from the Cochran-Armitage trend test.
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analysis for patients with larger breast volume yielded a sig-
nificant association for codon 751 of XPD (OR=3.95, 95%
CI: 0.91–22.75, p=0.046). Again, no significant association
was seen for the other four SNPs.
In addition to the single SNP analysis the association
of the combination of all SNPs with erythema was tested.
For that the allele associated with an increased risk of
erythema was defined as risk allele, which was: A-allele
for ATM and XRCC1, T-allele for TGFB1 and XPD and
G-allele for GSTP1. However, no significant association
with risk of erythema, either for all patients (OR= 1.20;
95% CI: 0.90-1.62; p= 0.209), patients with small breast
volume (OR= 1.36; CI: 0.94-2.04; p= 0.098) or for
patients with a large volume (OR= 0.89; CI: 0.52-1.50;
p= 0.712) was detected for this risk profile.
In Figure 2, Odd ratios (OR) as determined for these
five SNPs with respect to risk of erythema (taken from
Table 2) are compared with the OR previously deter-
mined for risk of fibrosis [22]. Obviously, there is a clear
difference between these profiles. In contrast to fibrosis
no SNP was found to be associated with an enhanced or
reduced risk of erythema (Figure 2, open bars) as indi-
cated by Odd ratios not significantly different from 1,0.
When this fibrosis related risk score was applied on the
erythema data set no significant association was
obtained, (OR= 0.94; CI: 0.71-1.25; p= 0.68). These find-
ings emphasizes that the risk of erythema or fibrosis are
clearly associated with different SNP profiles.
Discussion
There is great interest in establishing methods which can
be used to predict the individual risk of normal tissue1
















Figure 2 Association of SNPs in ATM, GSTP1, TGFB1, XPD and XRCC1 w
treated by conserving radiotherapy. Odd ratios (ORs) obtained are plott
from [22].effects after radiotherapy. If these risks were known prior
to the onset of therapy, the total dose applied could be
reduced in the small proportion of highly sensitive
patients and, conversely, radiation dose and possibly the
chance to cure could be increased for normal and resist-
ant patients [28,29].
For radiotherapy, the risk of side effects is considered to
be determined mostly by treatment-related factors such as
dose and dose per fraction, but also to a considerable ex-
tent by genetic parameters [5,30]. In this context, SNPs are
considered to be the best genetic markers [8].
Following a candidate gene approach, six polymorphisms
were selected in genes (ATM, GSTP1, TGFB1, SOD2, XPD,
XRCC1) that are known to be associated with the induction
or repair of DNA-damage [31-36]. In our first study on
breast cancer patients treated by conserving radiotherapy,
these SNPs were compared with the risk of severe
radiation-induced fibrosis [22]. For each SNP, only a weak
association was found, with p-values ranging between 0.064
and 0.643. However, combining all six SNPs into one risk
score yielded a highly significant association (p=0.0005).
In this study, we have now analysed the association of
the same SNPs with the risk of acute effects as observed
after breast conserving radiotherapy. In order to increase
the performance of the study, the inclusion criteria were
applied strictly for all treatment parameters; i.e. variation
in the total dose was negligible, as 50 or 50.4 Gy were
applied using only two fractionation regimes (2.0 or
1.8 Gy). Since total dose is considered to be a crucial factor
in studying genetic determinants of radiation response
[30], the detriment of a relatively small patient collective
was counterbalanced by the extremely homogenously per-
formed treatment.TT GT TT GA AA
(pos-509)         XPD(751)                XRCC1(399)
otype
ith risk of either erythema or fibrosis for breast cancer patients
ed vs. the respective gene variants. Data shown for fibrosis are taken
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effects was analyzed using the trend test, which reflects
the dosage effect of the number of mutant alleles. Due to
deviation from the Hardy-Weinberg-equilibrium, one
SNP (SOD2, codon 16) was excluded from the analysis
(Table 1). When the analysis was performed with all
patients, none of the five SNPs studied was found to
show a significant association with erythema (Table 2).
This is in line with most other studies in breast cancer
patients (for review see [8]) showing no significant asso-
ciation with acute effects for the vast majority of SNPs.
An association has only been found for GSTP1 codon
105 [37] - which was, however, not observed in our
report (Table 2) - as well as for SNPs in IL12RB2 and in
ABCA1 [38] as well as CD44, MAD2L2, PTTG1, RAD9A
and Lig3 [39].
Since a previous study [26] proved breast volume to be
of importance for the incidence of radiation induced
erythema, and other reports also verify breast size as an
important confounding factor in the development of radi-
ation-induced erythema [16,40-43] we performed an add-
itional analysis dichomising the patients according to their
breast volume. This analysis yields a significant association
of TGFB1 C-509 T for patients with smaller breast
volumes and XPD codon 751 for patients with larger
breast volume (Table 2). Due to relative small sample sizes
we abstained from Bonferoni-correction, following other
studies on this issue {[8,44,45] for Review see [8,46]. It can-
not be excluded that the observed differences in SNP asso-
ciations between breast size might be the result of random
fluctuations rather than being a reflection of a true differ-
ence in the radiobiology of large and small breasts,
respectively. Therefore verification studies are needed to
test the evolving hypothesis that different pathways and
with that different SNPs might be relevant for clinical
radiosensitivity according to breast size - and by that pos-
sibly to body mass index and metabolic parameters.
For the other four SNPs, no significant association was
found (Table 2), even when combined into a risk score.
These results indicate that probably due to differences be-
tween smaller and larger breasts with respect to micro-mi-
lieu and/or metabolism, other parameters and with them
other genes are of relevance for the formation of acute
effects. As a consequence, more significant associations
could potentially have been found in other reports if breast
volume had been considered as a relevant confounding
factor as done here (Table 2). It has also been shown that
the total dose applied must be considered as a relevant
confounding factor in a radiogenomic analysis [23,47].
Certainly more of these factors need to be taken into con-
sideration in order to detect the moderate effects caused
by a single SNP.
For the five SNPs studied, we also demonstrated that the
risk profile obtained for erythema was clearly differentfrom that previously found for fibrosis in breast cancer
patients treated by conserving radiotherapy [22]. There are
also several reports on breast conserving radiotherapy in
which the association between certain SNPs was compared
with both acute and late effects. The by far largest study
was performed by Chang-Claude and colleagues, analysing
the association between polymorphisms in certain DNA
repair genes and either acute [48] or late side effects [49].
Although these studies did not always use the same set of
polymorphisms, the data obtained confirm that for differ-
ent clinical endpoints, the risk is determined by different
combinations of SNPs. There are numerous reports inves-
tigating the impact of mutations in ATM on side effects in
breast cancer patients. A clear different influence was seen
in one study [50], but not in the others [51-53].
The results obtained in the present study indicate that
the endpoints of acute and late tissue toxicity are deter-
mined by different molecular and cellular pathways, re-
spectively. Therefore, analysing the association of SNPs
with both acute and late effects will help us not only to
identify the SNPs which might be used as markers of the
respective risks, but also to unravel the underlying bio-
logical mechanisms.
Conclusion
In summary, this study demonstrates for the first time that
significant associations between a specific SNP and risk of
erythema can be identified if breast cancer patients are
grouped by their breast volume. The combination of SNPs
using risk alleles according to erythema is substantially
different from a risk score previously defined for risk of
fibrosis. However, these results need to be replicated in an
independent and larger study.
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